Rita and Daniel launched a yeast-powered drug repurposing project on behalf of their son Milo, who has two pathogenic variants in his AFG3L2 gene. The TargetMol screen is happening this week.
AFG3L2 Cure Odyssey
AFG3L2 Cure Odyssey
AFG3L2 Cure Odyssey
Rita and Daniel launched a yeast-powered drug repurposing project on behalf of their son Milo, who has two pathogenic variants in his AFG3L2 gene. The TargetMol screen is happening this week.